### Additional file 2. Critical Appraisal Skills Programme (CASP) for a Randomised Controlled Trial.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Fleischmann et al.  | Gysin-Maillart, et al. | King et al. | Miller et al. |
| **1. Did the trial address a clearly focused issue?** | Yes | Yes  | Yes | Yes |
| **2. Was the assignment of patients to treatments randomised?**   | Yes | Yes  | Yes | No |
| **3. Were patients, health workers and study personnel blinded?**  | Patients - yesHealth workers –unclearAssessors - unclear | Patients - noHealth workers - noAssessors - no | Patients - yesHealth workers –unclearAssessors - yes | Patients - yesHealth workers - noAssessors -yes |
| **4. Were the groups similar at the start of the trial?** | Yes | Yes  | Unclear | Broadly similar |
| **5. Aside from the experimental intervention, were the groups treated equally?**  | Yes  | Yes  | Yes  | Unclear |
| **6. Were all of the patients who entered the trial properly accounted for at its conclusion?**  | Yes | Yes  | Yes | Yes |
| **7. How large was the treatment effect?**  | 90% relative risk reduction for completed suicides | 69% (RR = 0.31)80% hazard ratio | Large effect for depression(Cohen's d = 1.07); Moderate for hopelessness; Small for suicidal ideation & alcohol use | 20% relative risk reduction in repeat suicide attempts |
| **8. How precise was the estimate of the treatment effect?** | CI 0.02 to 4.45 | CI 0.12 to 0.80 (relative risk) CI 12.4 to 13.7 (hazard ratio) | CI not reported | CI 0.63 to 1.02 |
| **9. Can the results be applied in your context? (or to the local population?)**  | Yes | Yes  | Yes | Yes |
| **10. Were all clinically important outcomes considered?**  | Yes | Yes  | Yes | Yes |
| **11. Are the benefits worth the harms and costs?** | Yes | Yes  | Yes | Yes |